Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 614-637-2 | CAS number: 68603-75-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1980-10-21 to 1981-02-26
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study with acceptable restrictions (very few information on the tested substance reported and only male rats used)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- yes
- Test type:
- standard acute method
Test material
- Reference substance name:
- 1-({3-[(2-hydroxypropyl)[(9E)-octadec-9-en-1-yl]amino]propyl}amino)propan-2-ol; 1-({3-[(2-hydroxypropyl)amino]propyl}(octadecyl)amino)propan-2-ol; 1-({3-[hexadecyl(2-hydroxypropyl)amino]propyl}amino)propan-2-ol
- EC Number:
- 614-637-2
- Cas Number:
- 68603-75-8
- Molecular formula:
- R-N(CH2CHOHCH3)xCH2CH2CH2N(CH2CHOHCH3)y with x+y=3 and where R = alkyl
- IUPAC Name:
- 1-({3-[(2-hydroxypropyl)[(9E)-octadec-9-en-1-yl]amino]propyl}amino)propan-2-ol; 1-({3-[(2-hydroxypropyl)amino]propyl}(octadecyl)amino)propan-2-ol; 1-({3-[hexadecyl(2-hydroxypropyl)amino]propyl}amino)propan-2-ol
- Details on test material:
- - Name of test material (as cited in study report): DINORAM SL
- Physical state: dark brown liquid
- Lot/batch No.: 2852
No other data available
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Centre d'elevage Charles River France, 76410 Saint Aubin les Elbeuf
- Age at study initiation: not reported
- Weight at study initiation: Male : 120-140 g
- Fasting period before study: 16 h before dosing
- Housing: polycarbonate cages , 5 animals per cage.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least 3 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 25 °C
- Humidity (%): 60 ± 20 %
- Air changes (per hr): 11
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE
- no vehicle used
MAXIMUM DOSE VOLUME APPLIED: 25 mL/kg bw . The administered volume was not constant starting from 25 ml/ kg bw to 0.5 ml/kg bw for the lowest dose-level administered. - Doses:
- preliminary experiment: 5, 10, 15, 20 and 25 mL/kg bw ( 2 rats per dose) then 1, 3, 4, 5 and 10 mL/kg bw (10 rats per dose)
main experiment: 0.5, 1.0, 1.5, 2.0 and 3.0 mL/kg bw (10 rats per dose) - No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for clinical signs immediately upon dosing, 3 hours after dosing and daily thereafter for a total of 14 days. Body weights were measured immediately prior to dosing (Day 0) and on Days 4, 7 and 14.
- Necropsy of survivors performed: yes - Statistics:
- LD50 and confidence intervals: Litchfield & Wilcoxon (J. Pharmacol. Exp. Therap., 1949, 96, 99-113)
Results and discussion
- Preliminary study:
- 5, 10, 15, 20 and 25 mL/kg bw ( 2 rats per dose): all animals died between days 2 and 3. Prostration, piloerection, diarrhoea and abdominal swelling were noted prior to death.
3, 4, 5, 10 mL/kg bw (10 rats per dose): all animals died between days 2 and 3. Prostration, piloerection, diarrhoea and abdominal swelling were noted prior to death.
1 mL/kg bw (10 rats per dose): no fatalities
Effect levels
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 1 255 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 1 031 - < 1 534
- Remarks on result:
- other: All administered doses were expressed in volume. The final result (ie LD50) was expressed in weight taking into account that the relative density of the test item was 0.897 (see relative density chapter 4.4).
- Mortality:
- At 0.5 ml/kg bw : no deaths occured.
At 1 ml/kg bw : 2 rats died on day 4.
At 1.5 ml/kg bw : 4 rats died on day 7.
At 2 ml/kg bw : 7 rats died on day 4 and 2 additional rats died on day 7.
At 3 ml/kg bw : all rats died on day 4 - Clinical signs:
- other: - At 0.5 ml/kg bw : no clinical effects were noted all along the study. - At 1 ml/kg bw : a slight drowsiness was in all animals observed 1h and 3h after administration. 24 hours later (day 1) , drowsiness was still observed and mucoid diarrhoea was note
- Gross pathology:
- No macroscopic abnormalities were observed at necropsy.
Applicant's summary and conclusion
- Interpretation of results:
- other: Toxicity category 4 / Harmful
- Remarks:
- Criteria used for interpretation of results: other: CLP (Reg. 1272/2008/EC) and Directive 67/548/EEC
- Conclusions:
- Under these experimental conditions, the oral LD50 of the test item was 1255 (1031 - 1534) mg/kg bw in male rats with 95% confidence interval limits
- Executive summary:
The acute oral toxicity of the test item was evaluated in rats according to a method similar to OECD guideline 401 and in compliance with the principles of Good Laboratory Practice Regulations.
The test item was administered undiluted by oral route (gavage) to groups of ten male fasted Sprague-Dawley rats. In the preliminary experiment, the test item was administered at the dose-levels of 1, 3,4, 5, 10, 15, 20 and 25 mL/kg bw (relative density 0.897) and the animals were observed for 7 days. Based on these results, the dose-levels selected for the main experiment were 0.5, 1.0, 1.5, 2.0 and 3.0 mL/kg bw of the undiluted test item.
Clinical signs, mortality and body weight were checked for a period of up to 14 days following the single administration of the test item. All animals were subjected to necropsy. The LD50 was calculated according to Litchfield & Wilcoxon (J. Pharmacol. Exp. Therap., 1949, 96, 99-113).
No deaths occured at 0.5 ml/kg bw. At 1, 1,5 and 2ml/kg bw, 2, 4 and 9 rats died from day 4 to day 7 respectively. At 3 ml/kg bw, all rats died on day 4.
Generally clinical signs were drowsiness and mucoid diarrhoea (at 1 mL/kg bw and higher), prostration and piloerection (at 1.5 ml/kg bw and higher), abdominal swelling and dizziness (at 3 ml/kg bw). no clinical sighns were observed at 0.5 ml/kg bw.
No macroscopic abnormalities were observed at necropsy in any dose-groups.
Under these experimental conditions, the oral LD50 of the test item was 1255 (1031 - 1534) mg/kg bw in male rats with 95% confidence interval limits
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
